Abbott Laboratories Quarterly Balance Sheet
NYSE: ABTHealthcareMedical DevicesUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Abbott Laboratories financial position
As of Mar 31, 2026, Abbott Laboratories reported total assets of $110.43 billion, up 35.6% from a year earlier against total liabilities of $57.73 billion. Shareholders' equity stood at $52.06 billion, or 47.1% of assets. The company held $6.80 billion in cash and equivalents against $34.05 billion of debt, a net debt position of $27.24 billion.
The current ratio (current assets divided by current liabilities) was 1.39, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.65.
Summary generated from market data by MetaCap's automated system. Methodology
Abbott Laboratories balance sheet (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.80B | 8.52B | 7.51B | 6.95B | 6.53B | 7.62B | 7.56B | 6.99B | 6.28B | 6.90B | 6.71B | 7.83B |
| Short-Term Investments | 492.00M | 417.00M | 222.00M | 331.00M | 312.00M | 351.00M | 230.00M | 232.00M | 367.00M | 383.00M | 338.00M | 320.00M |
| Receivables | 8.21B | 7.93B | 8.14B | 7.97B | 7.33B | 6.92B | 7.05B | 6.85B | 6.61B | 6.57B | 6.50B | 6.17B |
| Inventory | 6.99B | 6.49B | 6.71B | 6.95B | 6.64B | 6.19B | 6.81B | 6.81B | 6.83B | 6.57B | 6.65B | 6.87B |
| Total Current Assets | 25.51B | 26.00B | 24.84B | 24.47B | 23.15B | 23.66B | 23.80B | 23.12B | 22.38B | 22.67B | 22.66B | 23.50B |
| Property, Plant & Equipment | 12.38B | 11.82B | 11.50B | 11.39B | 10.93B | 10.66B | 10.62B | 10.23B | 10.11B | 10.15B | 9.55B | 9.45B |
| Goodwill | 35.22B | 24.04B | 23.97B | 23.95B | 23.36B | 23.11B | 23.66B | 23.31B | 23.38B | 23.68B | 23.28B | 23.26B |
| Intangible Assets | 17.88B | 5.53B | 5.60B | 5.92B | 6.26B | 6.65B | 7.35B | 7.83B | 8.30B | 8.81B | 9.28B | 9.83B |
| Long-Term Investments | 1.09B | 918.00M | 951.00M | 958.00M | 907.00M | 886.00M | 912.00M | 877.00M | 818.00M | 799.00M | 788.00M | 799.00M |
| Total Assets | 110.43B | 86.71B | 84.18B | 84.00B | 81.45B | 81.41B | 74.36B | 73.02B | 72.47B | 73.21B | 72.09B | 73.35B |
| Accounts Payable | 4.68B | 4.24B | 4.12B | 4.31B | 4.21B | 4.20B | 4.03B | 4.13B | 4.18B | 4.29B | 3.96B | 4.21B |
| Short-Term Debt | 4.41B | 3.03B | 1.34B | 507.00M | 506.00M | 1.50B | 2.15B | 1.61B | 2.01B | 1.08B | 1.05B | 2.28B |
| Total Current Liabilities | 18.38B | 16.50B | 14.58B | 13.44B | 13.00B | 14.16B | 14.90B | 13.76B | 14.02B | 13.84B | 13.04B | 14.35B |
| Long-Term Debt | 29.64B | 9.90B | 11.60B | 12.93B | 12.74B | 12.63B | 12.82B | 13.14B | 12.58B | 13.60B | 14.48B | 14.56B |
| Total Liabilities | 57.73B | 33.94B | 32.92B | 33.17B | 32.38B | 33.51B | 34.33B | 33.46B | 33.42B | 34.39B | 34.40B | 35.95B |
| Shareholders' Equity | 52.06B | 52.13B | 50.95B | 50.56B | 48.81B | 47.66B | 39.80B | 39.32B | 38.81B | 38.60B | 37.48B | 37.17B |
| Retained Earnings | 49.96B | 49.78B | 49.10B | 48.47B | 47.72B | 47.26B | 39.06B | 38.35B | 38.01B | 37.55B | 36.92B | 36.35B |
| Total Debt | 34.05B | 12.93B | 12.94B | 13.44B | 13.24B | 14.13B | 14.98B | 14.75B | 14.59B | 14.68B | 15.53B | 16.85B |
| Net Cash (Debt) | -26.75B | -3.99B | -5.21B | -6.16B | -6.40B | -6.16B | -7.19B | -7.54B | -7.93B | -7.40B | -8.48B | -8.69B |
This table shows 12 quarterly periods of Abbott Laboratories's balance sheet, from Q1 2026 back to Q2 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ABT's reporting calendar. What is a balance sheet?